PL368802A1 - Aralkilotetrahydropirydyny, ich wytwarzanie i zawierajace je środki farmaceutyczne - Google Patents

Aralkilotetrahydropirydyny, ich wytwarzanie i zawierajace je środki farmaceutyczne

Info

Publication number
PL368802A1
PL368802A1 PL02368802A PL36880202A PL368802A1 PL 368802 A1 PL368802 A1 PL 368802A1 PL 02368802 A PL02368802 A PL 02368802A PL 36880202 A PL36880202 A PL 36880202A PL 368802 A1 PL368802 A1 PL 368802A1
Authority
PL
Poland
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
pyridines
tetrahydro
Prior art date
Application number
PL02368802A
Other languages
English (en)
Inventor
Marco Baroni
Bernard Bourrie
Rosanna Cardamone
Pierre Casellas
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of PL368802A1 publication Critical patent/PL368802A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
PL02368802A 2001-10-18 2002-10-14 Aralkilotetrahydropirydyny, ich wytwarzanie i zawierajace je środki farmaceutyczne PL368802A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0113469A FR2831166B1 (fr) 2001-10-18 2001-10-18 Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
PL368802A1 true PL368802A1 (pl) 2005-04-04

Family

ID=8868455

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02368802A PL368802A1 (pl) 2001-10-18 2002-10-14 Aralkilotetrahydropirydyny, ich wytwarzanie i zawierajace je środki farmaceutyczne

Country Status (21)

Country Link
US (2) US7326723B2 (pl)
EP (1) EP1438291B1 (pl)
JP (2) JP4524107B2 (pl)
KR (1) KR100935787B1 (pl)
CN (2) CN100335464C (pl)
AT (1) ATE303991T1 (pl)
AU (1) AU2002360117B2 (pl)
BR (1) BR0213359A (pl)
CA (1) CA2460822C (pl)
DE (1) DE60206068T2 (pl)
EA (1) EA007324B1 (pl)
FR (1) FR2831166B1 (pl)
HU (1) HUP0401713A3 (pl)
IL (2) IL160820A0 (pl)
IS (1) IS2486B (pl)
MX (1) MXPA04003568A (pl)
NO (1) NO326490B1 (pl)
NZ (1) NZ531846A (pl)
PL (1) PL368802A1 (pl)
WO (1) WO2003033466A1 (pl)
ZA (1) ZA200402059B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60216310T2 (de) 2001-10-15 2007-06-21 Janssen Pharmaceutica N.V. Substituierte 4-phenyl-4-(1h-imidazol-2-yl)-piperidinderivate zur verringerung von ischämischer schädigung
CN100526301C (zh) * 2003-12-26 2009-08-12 卫材R&D管理有限公司 1,2-二(环式基)取代苯化合物
US7410971B2 (en) 2003-12-26 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
US20060276465A1 (en) * 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
EP1832580A4 (en) 2004-12-20 2009-03-11 Eisai R&D Man Co Ltd 1-CYCLOPROPYLMETHYL-4-Ý2- (3,3,5,5) -TETRAMETHYLCYCLOHEXYL) PHENYL PIPERAZINE CRYSTAL AND SALT
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
US9493383B2 (en) 2005-09-15 2016-11-15 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
US8298683B2 (en) * 2005-09-15 2012-10-30 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
US9608205B2 (en) 2005-09-15 2017-03-28 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
WO2009149363A1 (en) * 2008-06-05 2009-12-10 Medical College Of Wisconsin, Inc. Three dimensional tissues for high-throughput assays

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3804878A (en) * 1969-09-08 1974-04-16 Ciba Geigy Corp Hydrogenated araliphatic acids
EP0447116B1 (en) * 1990-03-12 1994-12-14 Yamanouchi Pharmaceutical Co. Ltd. Urea derivatives, their production, and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
DE69520360T2 (de) * 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
FR2734819B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2762514B1 (fr) * 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
US6070784A (en) * 1998-07-08 2000-06-06 The Boeing Company Contact backup roller approach to FSW process
MXPA02003979A (es) * 1999-10-22 2003-01-28 Sanofi Synthelabo Fenil- y piridil-tetrahidro-piridinas que tiene una actividad inhibidora de tnf.
DE60011817T2 (de) * 1999-12-30 2005-07-14 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl und -tetrahydropyridyl-derivate
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
US7186720B2 (en) * 2001-04-20 2007-03-06 Sanofi-Aventis Tetrahydropyridyl-alkyl-heterocycles, method for preparing the same and pharmaceutical compositions containing the same
FR2823749B1 (fr) * 2001-04-20 2004-02-20 Sanofi Synthelabo Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant
JP3687912B2 (ja) * 2002-08-29 2005-08-24 東芝テック株式会社 プリンタユニット

Also Published As

Publication number Publication date
DE60206068D1 (de) 2005-10-13
ZA200402059B (en) 2005-03-15
MXPA04003568A (es) 2004-07-30
FR2831166A1 (fr) 2003-04-25
NZ531846A (en) 2005-10-28
EA200400323A1 (ru) 2004-10-28
IL160820A (en) 2009-06-15
CA2460822C (en) 2011-01-04
DE60206068T2 (de) 2006-07-13
CA2460822A1 (en) 2003-04-24
US7326723B2 (en) 2008-02-05
IS7181A (is) 2004-03-11
NO20041573L (no) 2004-07-07
JP2010120961A (ja) 2010-06-03
CN100335464C (zh) 2007-09-05
JP4524107B2 (ja) 2010-08-11
IS2486B (is) 2008-12-15
EP1438291A1 (fr) 2004-07-21
WO2003033466A1 (fr) 2003-04-24
CN101096337A (zh) 2008-01-02
BR0213359A (pt) 2004-10-26
KR100935787B1 (ko) 2010-01-06
KR20050036866A (ko) 2005-04-20
HUP0401713A3 (en) 2012-08-28
HK1065543A1 (en) 2005-02-25
EP1438291B1 (fr) 2005-09-07
JP2005505621A (ja) 2005-02-24
IL160820A0 (en) 2004-08-31
FR2831166B1 (fr) 2004-02-27
CN1571770A (zh) 2005-01-26
AU2002360117B2 (en) 2008-07-17
US20050014795A1 (en) 2005-01-20
NO326490B1 (no) 2008-12-15
EA007324B1 (ru) 2006-08-25
ATE303991T1 (de) 2005-09-15
US20080097117A1 (en) 2008-04-24
HUP0401713A2 (hu) 2004-12-28
US7858824B2 (en) 2010-12-28

Similar Documents

Publication Publication Date Title
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
BG103485A (en) Ketobanzamides as calpain inhibitors
GEP20074133B (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
IL127058A0 (en) Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
YU89402A (sh) 5-hloro-3-(4-metansulfonilfenil)-6'-metil-/2,3'/bipiridinil u čistom kristalnom obliku i postupak sinteze
MXPA02012921A (es) Nueva forma cristalina beta de la sal de ter-butilamina de perindopril, su metodo de preparacion y composiciones farmaceuticas que la contienen.
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
IL160820A0 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
UA83648C2 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
IL143625A0 (en) Sulfonamide hydroxamates
YU76500A (sh) Hemijska sinzeza morfolinskih derivata
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
AU2002246317A1 (en) Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
HU0004701D0 (pl)
YU30499A (sh) Endotelin intermedijari dobijeni pomoću asimetrične konjugovane adicione reakcije koristeći hiralni aditiv
EA200300400A1 (ru) 17α-ФТОРАЛКИЛСТЕРОИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner
IL154915A0 (en) Method for producing chiral compounds
EP1057829A4 (en) Condensed pyrimidine derivatives and pharmaceutical compositions containing them
MXPA04002784A (es) Sales farmaceuticamente aceptables de 20(s)-camptotecinas.
GB9924759D0 (en) Process for preparing peptide intermediates
CA2426221A1 (en) New neurokinin antagonists, processes for preparing them and pharmaceutical compositions containing these compounds

Legal Events

Date Code Title Description
VOID Decisions declaring the decisions on the grant of the patent lapsed